Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 31/5/2020
SIETES contiene 93020 citas

 
 
 1 a 20 de 29 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Schiek S, Hildebrandt K, Zube O, Bertsche T. Fall-risk-increasing adverse reactions - is there value in easily accessible drug information? A case-control study. Eur J Clin Pharmacol 2019;75:junio. [Ref.ID 103137]
2.Enlace a cita original Cita con resumen
Friedman BW, Irizarry E, Solorzano C, Latev A, Rosa K, Zias E, Vinson DR, Bijur PE, Gallagher EJ. Randomized study of IV prochlorperazine plus diphenhydramine vs IV hydromorphone for migraine. Neurology 2017:18 de octubre. [Ref.ID 102194]
3. Cita con resumen
Shaheed CA, Maher CG, Williams KA, Day R, McLachlan AJ. Efficacy, tolerability, and dose-dependent effects of opioid analgesics for low back pain: a systematic review and meta-analysis. JAMA Intern Med 2016;176:958-68. [Ref.ID 100298]
4. Cita con resumen
Scholten W. Paediatric morphine dosages. WHO Pharmaceuticals Newsletter 2012;4:26-8. [Ref.ID 93684]
5. Cita con resumen
Anónimo. Opioïdes et hypogonadisme. Prescrire 2012;32:27-8. [Ref.ID 92255]
6. Cita con resumen
Dublin S, Walker RL, Jackson ML, Nelson JC, Weiss NS, Von Korff M, Jackson LA. Use of opioids or benzodiazepines and risk of pneumonia in older adults: A population-based case–control study. J Am Geriatr Soc 2011;59:1899-907. [Ref.ID 91710]
7. Cita con resumen
Schneider MF, Bailey JE, Cicero TJ, Dart RC, Inciardi JA, Parrino M, Muñoz A. Integrating nine prescription opioid analgesics and/or four signal detection systems to summarize statewide prescription drug abuse in the United States in 2007. Pharmacoepidemiol Drug Saf 2009;18:778-90. [Ref.ID 86559]
8. Cita con resumen
Anónimo. Hidromorfona Jurnista® (Janssen Cilag). PAM 2008;32:427-35. [Ref.ID 83176]
9.Enlace a cita original Cita con resumen
Anónimo. Uso de opioides en el tratamiento del dolor oncológico. Boletín Terapéutico Andaluz 2007;23:9-12. [Ref.ID 80839]
10. Cita con resumen
Jalan R, Williams R, Bernuau J. Paracetamol: are therapeutic doses entirely safe?. Lancet 2007;368:2195-6. [Ref.ID 78712]
11.Tiene citas relacionadas Cita con resumen
Amabile CM, Bowman BJ. Overview of oral modified-release opioid products for the management of chronic pain. Ann Pharmacother 2006;40:1327-35. [Ref.ID 77893]
12. Cita con resumen
Watkins PB, Kaplowitz N, Slattery JT, Colonese CR, Colucci SV, Stewart PW, Harris SC. Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily. A randomized controlled trial. JAMA 2006;296:87-93. [Ref.ID 77581]
13.
Anónimo. Hydromorphone extended release suspended. WHO Drug Information 2005;19:217. [Ref.ID 75411]
14.
Anónimo. Hydromorphone hydrochloride. To be withdrawn for safety reasons. USA. WHO Pharmaceuticals Newsletter 2005;3:3. [Ref.ID 74932]
15.
Anónimo. Palladone for chronic pain. Med Lett Drugs Ther 2005;47:21-3. [Ref.ID 73239]
16.
Hain RDW, Miser A, Devins M, Wallace WHB. Strong opioids in pediatric palliative medicine. Pediatr Drugs 2005;7:1-9. [Ref.ID 73144]
17.
Anderson SL, Shreve ST. Continuous subcutaneous infusion of opiates at end-of-life. Ann Pharmacother 2004;38:1015-23. [Ref.ID 70220]
18.
Anónimo. Fluoxétine + hydromorphone: syndrome sérotoninergique?. Prescrire 2003;23:834. [Ref.ID 68573]
19. Cita con resumen
Anónimo. Hydromorphone: pas mieux que la morphine per os. Prescrire 2000;20:327-9. [Ref.ID 50737]
20. Cita con resumen
Joranson DE, Ryan K M, Gilson AM, Dahl JL. Trends in medical use and abuse of opioid analgesics. JAMA 2000;283:1710-4. [Ref.ID 50286]
Seleccionar todas
 
 1 a 20 de 29 siguiente >>